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A 68-year-old man with hemophilia A and liver cirrhosis caused by hepatitis C virus was referred to our hospital to receive
prophylactic endoscopic treatment for gastroesophageal varices (GOV). He had large, tense, and winding esophageal varices (EV)
with cherry red spots extending down to lesser curve, predicting the likelihood of bleeding. Esophageal endoscopic injection
sclerotherapy (EIS) was performed with a total 15mL of 5% ethanolamine oleate with iopamidol (EOI). Radiographic imaging
during EIS demonstrated that 5% EOI reached the aﬀerent vein of the varices. He was administered suﬃcient factor VIII
concentrate before and after EIS to prevent massive bleeding from the varices. Seven days after EIS, upper gastrointestinal
endoscopy (UGIE) showed that the varices were eradicated almost completely. Eighteen months after EIS, the varices continued to
diminish. We report a successful case of safe and eﬀective EIS for GOV in a high-risk cirrhotic patient with hemophilia A.
1.Introduction
Portalhypertensionisoneofthemajorcomplicationsofliver
cirrhosis and results in the development of esophagogastric
varices (EGV). Before virus-free coagulation factor concen-
trates became available in 1987, most hemophilic patients
treated by the concentrates were infected by hepatitis B
(HBV) and/or hepatitis C virus (HCV). While these viral
infections are frequently asymptomatic at an early stage,
liver dysfunction gradually progresses and ultimately leads
to liver cirrhosis [1]. In cirrhotic patients with hemophilia,
bleeding from EGV leads to a very serious clinical condition,
which is diﬃcult to control due to coagulation disorders and
decreasedplatelet count.Therefore,the managementof EGV
is especially important in these patients in order to improve
their prognosis.
We performed prophylactic endoscopic injection scle-
rotherapy (EIS) with supplementation of factor VIII con-
centrateforhigh-riskgastroesophagealvarices(GOV)(large,
tense, and winding esophageal varices (EV) with cherry
red spots extending down to lesser curve) in a 68-year-
old Japanese cirrhotic patient with hemophilia A. A single
EIS session eradicated the varices almost completely and no
recurrence of varix was observed until eighteen months after
the treatment, which indicated the usefulness and eﬃcacy of
the procedure.
2.CaseReport
A 68-year-old Japanese man with hemophilia A and liver
cirrhosis was referred to our hospital because of large, tense,
andwindingEVwithcherryredspotsextendingfrommiddle
esophagus down to lesser curve, classiﬁed as type 1 GOV
(GOV1) [2, 3] (Figures 1(a) and 1(b)). He was diagnosed
with hemophilia A and chronic hepatitis C at 40 years of age.
Hepatitis C was treated with ursodeoxycholic acid (UDCA)2 Gastroenterology Research and Practice
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Figure 1: GOV before EIS. (a, b) UGIE showed large, tense, and
winding EV with cherry red spots extending down to lesser curve.
and stronger neo-minophagen C (SNMC), while hemophilia
A required no medical treatment. The patient had no
previous history of bleeding from EGV. On admission, his
consciousness level was alert and hepatic encephalopathy
was not present. Computed tomography (CT) and ultra-
sonography (US) showed cirrhotic liver without ascites.
DynamicCTshowedthatthevaricesweresuppliedbytheleft
gastric vein (LGV). Laboratory ﬁndings showed the follow-
ing: alanine aminotransferase (AST), 58IU/L (12–35IU/L);
aspartate aminotransferase (ALT), 52IU/L (6–33IU/L);
total bilirubin (T-Bil), 1.08mg/dL (0.2–1.0mg/dL); albu-
min (ALB), 3.5g/dL (3.9–5.2g/dL); white blood cell
count (WBC), 2600/mm3 (3400.2–7300/mm3); hemoglobin
(Hb), 12.8g/dL (12.5–15.9g/dL); platelet count (PLT),
42000/mm3(160000–327000/mm3);prothrombintime(PT),
86%; factor VIII activity, 16.4% (78.0–165.0%); activated
partial thromboplastin time (APTT), 60.4 second (24.2–34.1
second); and Child-Pugh classiﬁcation, grade A. He was
positive for antibody to HCV, but negative for HBV surface
antigen and antibody to human immunodeﬁciency virus
(HIV).
We obtained written informed consent for EIS and factor
VIII concentrate supplementation from the patient before
the procedure. According to the guidelines for the man-
agement of hemophilia published by the World Federation
of Hemophilia in 2005 [4], the patient was administered a
dose of 50U/kg of factor VIII complex supplementation in
order to achieve activity greater than 100% of the normal
level to prevent massive bleeding from the varices; 3000U
of factor VIII was injected 1 hour before and 12 hours after
EIS on the ﬁrst day, and every 24 hours until the ﬁfth post-
operative day, resulting in 104% increase in plasma level of
factor VIII activity in the patient after the injections. The
total amount of factor VIII supplementation was 21,000U.
EsophagealEISwasperformedbyintravaricealinjectionwith
a total 15mL of 5% ethanolamine oleate with iopamidol
(EOI) for three varices at middle esophagus (Figure 2(a)).
Radiographic imaging during EIS demonstrated that 5%
EOI reached the LGV, which was the aﬀerent vein of the
GOV (Figure 2(b)). No para-operative complications were
observed during and after EIS. Seven days after EIS, upper
gastrointestinal endoscopy (UGIE) showed that the varices
were eradicated almost completely without cherry red spots
(Figures 3(a) and 3(b)), and endoscopic ultrasonography
(EUS) showed high echoic areas in the lumen of the varices
(Figure 3(c)), indicating the formation of thrombi in the
aﬀerent vessels as well as the varices. At follow-up endoscopy
eighteenmonthsafterthetreatment,thevaricescontinuedto
diminish without visible cherry red spots (Figures 4(a) and
4(b)), however, the appearance of esophageal telangiectasia
and portal hypertensive gastropathy was observed.
3. Discussion
It is very diﬃcult to control hemorrhagic incidents in
hemophiliacs because of their coagulation disorders that
invasive treatments such as tooth extractions and surgery
proved problematic in the past. In recent years, however, as
a result of advancements in coagulation factor replacement
therapy, hemophiliacs have been able to receive invasive
treatments as safely as other nonhemophiliacs. Even invasive
endoscopic treatments like sclerotherapy are possible for
hemophiliacsthroughasuﬃcientsupplementationofcoagu-
lation factors. The transfusion requirement can be calculated
based on the desired increase in activity level targeted to each
clinical situation [5]. Generally, the prophylactic endoscopic
treatment for EV indicates EIS and EVL. The results of
randomized controlled studies evaluating prophylactic EIS
have been controversial [6–10]; some studies have shown a
signiﬁcant beneﬁt [6–8], but others have not [9, 10]. The tri-
als including patients with high-risk esophageal varices have
illustrated that prophylactic EIS reduces the incidence of the
ﬁrst variceal bleeding and prolongs survival [6, 7]. Gotoh et
al. concluded that recurrence of varices was more frequent in
patients treated with EVL than EIS, suggesting that EVL was
not recommended for prophylactic therapy of EV in liver cir-
rhosis[8].Inothertrials,however,EVLhasbeenshowntobe
equal in eﬀect to EIS, but with fewer complications [11–13].
In the cases of hemophilia with EV, there were, thus far,
two reported cases of endoscopic treatment for EV [14, 15],
but there was no reported case for GOV in literature. One
of the cases was successfully treated by EVL [14]. In this
case, the author recommended EVL but not EIS, because
EVL produced shallow circular ulcers that resolved moreGastroenterology Research and Practice 3
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Figure 2: EIS procedure. (a) EIS was performed by intravariceal injection of 15mL of 5% EOI in total. (b) Radiographic imaging showed
that 5% EOI reached the cardiac plexus and LGV.
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Figure 3: GOV seven days after EIS. (a, b) UGIE showed that the varices were eradicated almost completely without cherry red spots. (c)
EUS showed high echoic areas in the lumen of the varices, indicating that the varices were completely thrombosed after EIS.4 Gastroenterology Research and Practice
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Figure 4: GOV eighteen months after EIS. (a, b) Follow-up
endoscopy showed that the varices continued to shrink.
rapidly than the deep linear ulcers caused by EIS [14].
The other patient was treated by EIS [15]. The author
concluded that patients could be safely treated with either
E V Lo rE I Si fp e r f o r m e db ya ne x p e r t[ 15]. In these cases,
the coagulation factor replacement therapy was performed,
and it was deemed as the eﬀective procedure to prevent
hemorrhagic incidents after the treatments. In contrast to
these cases of EV, however, our patient had gastric varices
(GV) in combination with EV. Esophageal EIS also can
obliterate associated GOV in a large proportion of patients,
dependingontheGVtype[2,3]andledtothedisappearance
of 30% to 60% of GOV1 within six months [2, 3, 16]. This is
likelytobecausedbycaudalﬂowofsclerosanttowardtheGV
[3]. Because of the possibility that GOV may disappear after
esophageal EIS, it has been recommended that in patients
with GOV, the EV should ﬁrst be treated, and if after six
months the GV persist, then speciﬁc therapy for GV should
be considered if indicated [2, 3]. For these reasons, we
selected not EVL but EIS and succeeded in eradicating GV
almost completely together with EV. Eighteen months after
the procedure, the varices continued to diminish.
In the reported case of EVL for EV in a hemophiliac
patient, bleeding from one of the ulcers caused by EVL was
suspected as the cause of melena eight days after EVL [14].
In addition, one year after two EVL sessions, variceal growth
was observed and two additional EVL sessions was needed
to achieve variceal eradication [14]. We estimated that the
late risk of hemorrhaging from treatment-related ulcers after
EIS could be reduced by suﬃcient supplementation of the
coagulationfactorconcentratesandappropriateintravariceal
injection of 5% EOI. Additionally, compared to EVL, the
sessions of treatment can be reduced by performing EIS with
suﬃcient occlusion of the aﬀerent vessels. The reduction of
the sessions of treatment can also contribute to reducing
the expense of coagulation factor supplementation. Because
sclerotherapy is considered to be a major surgical procedure
for which current guidelines recommend that an activity of
70–100% should be achieved [4], we administered factor
VIII complex to the patient to achieve a 100% activity
level of factor VIII. The half-life of factor VIII products is
about 8 to 10 hours, and thus factor VIII was supplemented
every 12 hours on the ﬁrst day. With suﬃcient factor VIII
supplementation,weperformedEISbystabbingthreevarices
and injecting 5% EOI with time lag adequate to completely
occlude patients’ aﬀerent vessels, LGV. The supplementation
of factor VIII prevented bleeding from treatment-related
ulcers after EIS. In this way, a single EIS session eradicated
the varices almost completely without any complications.
In a follow-up endoscopic study eighteen months after EIS,
no recurrent EGV were observed. There has been no other
reported case that, like our case, succeeded in eradicating GV
together with EV in one session with relatively fewer doses
of coagulation factors and without recurrence of varix for a
relatively long period.
In conclusion, when performing endoscopic treatments
for high-risk patients such as hemophiliacs, it is very impor-
tant to appropriately manage their respective conditions
through suﬃcient coagulation factor supplementation in
addition to attentively performing EIS in order to prevent
hemorrhagic complications.
References
[ 1 ]J .J .G o e d e r t ,M .E .E y s t e r ,M .M .L e d e r m a n ,e ta l . ,“ E n d -
stageliverdiseaseinpersonswithhemophiliaandtransfusion-
associated infections,” Blood, vol. 100, no. 5, pp. 1584–1589,
2002.
[2] S. K. Sarin, D. Lahoti, S. P. Saxena, N. S. Murthy, and U.
K. Makwana, “Prevalence, classiﬁcation and natural history
of gastric varices: a long-term follow-up study in 568 portal
hypertension patients,” Hepatology, vol. 16, no. 6, pp. 1343–
1349, 1992.
[3] B. M. Ryan, R. W. Stockbrugger, and J. M. Ryan, “A patho-
physiologic, gastroenterologic, and radiologic approach to the
management of gastric varices,” Gastroenterology, vol. 126, no.
4, pp. 1175–1189, 2004.
[4] WorldFederationofHemophilia,“GuidelinesfortheManage-
ment of Hemophilia,” 2005.
[5] B. Furie, S. A. Limentani, and C. G. Rosenﬁeld, “A practical
guide to the evaluation and treatment of hemophilia,” Blood,
vol. 84, no. 1, pp. 3–9, 1994.
[6] K.-J.Paquet,J.-F.Kalk,C.-P.Klein,andH.A.Gad,“Prophylac-
tic sclerotherapy for esophageal varices in high-risk cirrhoticGastroenterology Research and Practice 5
patients selected by endoscopic and hemodynamic criteria:
a randomized, single-center controlled trial,” Endoscopy, vol.
26, no. 9, pp. 734–740, 1994.
[ 7 ] G .P i a i ,L .C i p o l l e t t a ,M .C l a a r ,e ta l . ,“ P r o p h y l a c t i cs c l e r o t h e r -
apy of high-risk esophageal varices: results of a multicentric
prospective controlled trial,” Hepatology,v o l .8 ,n o .6 ,p p .
1495–1500, 1988.
[8] Y. Gotoh, R. Iwakiri, Y. Sakata, et al., “Evaluation of endo-
scopic variceal ligation in prophylactic therapy for bleeding of
oesophageal varices: a prospective, controlled trial compared
with endoscopic injection sclerotherapy,” Journal of Gastroen-
terology and Hepatology, vol. 14, no. 3, pp. 241–244, 1999.
[ 9 ]R .P o t z i ,P .B a u e r ,R .S c h ¨ oﬂ, et al., “Prophylactic endoscopic
sclerotherapy of esophageal varices in liver cirrhosis—long-
term follow-up and ﬁnal results of a multicenter prospective
controlled randomized trial in Vienna,” Endoscopy, vol. 25, no.
4, pp. 287–289, 1993.
[ 1 0 ]H .K o c h ,K .F .B i n m o e l l e r ,H .G r i m m ,N .S o e h e n d r a ,H .
Henning, and G. Oehler, “Prophylactic sclerotherapy for
esophageal varices: long-term results of a prospective study,”
Endoscopy, vol. 26, no. 9, pp. 729–733, 1994.
[11] J. S. Goﬀ, R. M. Reveille, and G. Van Stiegmann, “Endoscopic
sclerotherapy versus endoscopic variceal ligation: esophageal
symptoms, complications, and motility,” The American Jour-
nal of Gastroenterology, vol. 83, no. 11, pp. 1240–1244, 1988.
[12] M. Hashizume, M. Ohta, K. Ueno, K. Tanoue, S. Kitano,
and K. Sugimachi, “Endoscopic ligation of esophageal varices
comparedwithinjectionsclerotherapy:aprospectiverandom-
ized trial,” Gastrointestinal Endoscopy, vol. 39, no. 2, pp. 123–
126, 1993.
[13] Y. Hata, E. Hamada, M. Takahashi, et al., “Endoscopic
variceal ligation is a suﬃcient procedure for the treatment
of oesophageal varices in patients with hepatitis C liver
cirrhosis: comparison with injection sclerotherapy,” Journal of
Gastroenterology and Hepatology, vol. 14, no. 3, pp. 236–240,
1999.
[14] M. Yamada, Y. Fukuda, Y. Koyama, et al., “Prophylactic
endoscopic ligation of high-risk oesophageal varices in a
cirrhoticpatientwithseverehaemophiliaA,”EuropeanJournal
ofGastroenterologyandHepatology,vol.10,no.2,pp.151–153,
1998.
[15] S. Kayashima, N. Murashima, K. Takei, et al., “A case of
hemophilia B with esophageal varices treated by sclerotherapy
with factor-IX complex,” Digestive Endoscopy, vol. 11, no. 4,
pp. 341–344, 1999.
[16] B. K. De, U. C. Ghoshal, A. S. Das, S. Nandi, and D.
N. Mazumder, “Portal hypertensive gastropathy and gastric
varices before esophageal variceal sclerotherapy and after
obliteration,” Indian Journal of Gastroenterology, vol. 17, no.
1, pp. 10–12, 1998.